 Unicycive Therapeutics Inc NASDAQ: UNCY updated the development and regulatory filing pathway for Renazorb lanthanum dioxycarbonate. Renazorb is a second-generation lanthanum-based phosphate-binding agent utilizing proprietary nanoparticle technology for hyperphosphatemia in patients with chronic kidney disease CKD. 